QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal second quarter 2021 financial results after market close on Thursday, August 5, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Ea

Quidel to Hold Fiscal Second Quarter 2021 Financial Results Conference Call on August 5th, 2021

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that the company has received the CE Mark for its innovative Savanna® multiplex molecular analyzer and Savanna® RVP4 Assay (Respiratory Viral Panel-4). The CE Mark allows Quidel to market and sell the Savanna system in Europe, as well as other countries that accept the CE Mark. Savanna

Quidel Receives CE Mark for Savanna® Multiplex Molecular Analyzer and Respiratory Viral Panel

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--Americans looking for information regarding Lyme disease have a new and trusted resource in which to rely with the launch of LymeDiseaseAnswers.com.

New Website Created by Quidel Corporation Provides Consumers With Information and Easy-to-Understand Answers Regarding Lyme Disease

Quidel Corporation (NASDAQ: QDEL) is recalling its Lyra COVID-19 Assay test due to a high risk of false-negative results in patients with high amounts of the virus. The FDA gave the molecular COVID-19 test emergency use authorization in March 2020.

Quidel Recalls Lyra COVID Diagnostic Test Due To Potential False Negative Results

A Covid-19 swab test is being recalled due to a risk of false negative results.

Quidel recalls Lyra Covid test due to high risk of false negative results

There might be a surge in demand for coronavirus testing kits in the very near future.

Why Quidel Shot 4% Higher Today

SAN DIEGO, Calif.--(BUSINESS WIRE)-- #LymeDisease--To help camp directors and counselors heighten their awareness of Lyme disease, a public service campaign has been launched by Quidel Corporation.

Public Service Campaign From Quidel Corporation Directed Toward Heightening Awareness Among Summer Camps of the Dangers of Lyme Disease

Quidel's strong organic growth potential and overall high growth market opportunities were previously analysed.

Quidel: Primed For Acquisitions

Quidel (QDEL) closed at $114.96 in the latest trading session, marking a +1.87% move from the prior day.

Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know

SAN DIEGO--(BUSINESS WIRE)-- #LymeDisease--Lyme disease is on the rise nationwide and has the potential to affect as many as 476,000 citizens before the year is out.

With Lyme Disease on the Rise Nationwide, Quidel Corporation Urges Early Testing With Its Rapid Point-of-Care Test

PerkinElmer

We believe that there are other stocks in the healthcare sector that are currently better valued than Aboott Laboratories. Abbott's current price-to-operating income ratio (P/EBIT) of 30x is much higher than levels of under 12x for PerkinElmer, and 4x for Quidel.

These Stocks Are Better Priced Compared To Abbott

Ionis Pharma

Scotts Miracle-Gro

Analysts view all three as rebound candidates.

3 Stocks Wall Street Thinks Will Skyrocket 50% or More

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received an amended Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) allowing the company to market Sofia® Q, its latest addition to the Sofia® and Sofia® 2 line of Fluorescent Immunoassay Analyzers (FIA). Sofia Q features a sleek, miniaturized

Quidel Receives Amended Emergency Use Authorization for New Sofia® Q Rapid Antigen Test Device

Bear of the Day: Quidel (QDEL)

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the Raymond James Human Health Innovation Conference 2021 to be held virtually on Monday, June 21, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 1:20 p.m. Eastern time (10:20 a.m. Pacifi

Quidel to Present Virtually at Raymond James Human Health Innovation Conference 2021

We believe that the stock price of Quidel, a clinical genetic testing company, looks undervalued at current levels near $108. QDEL stock is actually up just 22% from levels of around $88 it was at on March 23, 2020, when broader markets made a bottom.

Here's Why We Believe Quidel Stock Is Undervalued

We think that Quidel currently is a better pick compared to Abbott. QDEL stock trades at about 3.1x trailing revenues, compared to around 5.6x for Abbott.

After A Large Decline Is Quidel A Better Bet Compared To Abbott Stock?

Alpha Pro Tech

Gilead Sciences

iBio

Inovio Pharmaceuticals

Novavax

Sorrento Therapeutics Inc

The pandemic bolstered many stocks to buy. But with cases fading, this narrative is now questionable.

7 Former Pandemic Stocks to Buy That Are No Longer Running Hot

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 41st Annual Growth Stock Conference to be held virtually on Thursday, June 3, 2021. Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on that day at 10:40 a.m. Central time (8:40 a.m. Pacific time) in

Quidel to Present Virtually at William Blair 41st Annual Growth Stock Conference

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that its Sofia® SARS Antigen FIA is the first rapid antigen test to receive authorization from Health Canada for serial testing for the detection of active coronavirus infection in both symptomatic and asymptomatic populations. The Sofia SARS Antigen FIA is a lateral flow immunofluores

Health Canada Approves Quidel's Sofia® SARS Antigen FIA Test for Screening of Asymptomatic Populations With Serial Testing

Investors rewarded the stock for triple-digit growth, but the market remains unsure about the remainder of 2021.

Why Quidel Stock Jumped Today

Quidel (QDEL) delivered earnings and revenue surprises of -10.06% and 0.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Quidel (QDEL) Misses Q1 Earnings Estimates

Quidel Corporation (QDEL) CEO Doug Bryant on Q1 2021 Results - Earnings Call Transcript

Shares of Quidel (NASDAQ:QDEL) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 259.02% year over year to $4.38, which missed the estimate of $4.71.

Quidel: Q1 Earnings Insights

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first quarter ended March 31, 2021. First Quarter 2021 Highlights Total revenue increased 115% to $375.3 million, from $174.7 million in the first quarter of 2020. Total sales of COVID-19 products were $280.3 million, as compared to $1.0 million in the first quarter of 2020. Tot

News for QuidelOrtho Corp Stock (QDEL)